Compare MTDR & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTDR | ALKS |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 7.5B |
| IPO Year | 2011 | 2012 |
| Metric | MTDR | ALKS |
|---|---|---|
| Price | $52.81 | $51.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 14 |
| Target Price | ★ $63.07 | $43.43 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,696,277,000.00 | $1,475,899,000.00 |
| Revenue This Year | $7.15 | $24.26 |
| Revenue Next Year | $7.63 | $4.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.46 | N/A |
| 52 Week Low | $37.14 | $25.17 |
| 52 Week High | $66.84 | $55.67 |
| Indicator | MTDR | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 60.77 |
| Support Level | $52.34 | $27.78 |
| Resistance Level | $57.65 | $55.67 |
| Average True Range (ATR) | 1.45 | 1.98 |
| MACD | 0.53 | -0.58 |
| Stochastic Oscillator | 76.15 | 35.07 |
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream. The company generates majority of its revenue from the exploration and production segment.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.